Bioactive Products
| A unique collection of 552 Anti-inflammatory natural compound library for Anti-inflammatory screening and New Anti-inflammatory drug research | ||
| Catalog No: | B72a26 | Anti-inflammatory Compound Library Screening Details |
| Size: | 1mg/well * 552 Compounds 2mg/well * 552 Compounds | |
| Cat. No. | Information |
| CFN98531 | Miltirone Miltirone is a CYPs inhibition, it has been characterized as a low-affinity ligand for central benzodiazepine receptors, it might ameliorate the symptoms associated with discontinuation of long-term administration of ethanol or of other positive modulators of the GABA A receptor. Miltirone possesses significant anticancer, antibacterial, antioxidant, and anti-inflammatory activities, the hepatocyte metabolism is the major route of clearance for miltirone. Miltirone is collateral sensitive in multidrug-resistant P-gp-overexpressing cells, induces G2/M arrest, and triggeres apoptosis via ROS-generated breakdown of MMP and DNA damage. Miltirone has antiprotozoal activity against T. brucei rhodesiense STIB 900. |
| CFN98532 | Dehydromiltirone Dehydromiltirone has antioxidant activity, it shows significant anti-neuroinflammatory effects through inhibiting PI3K/Akt phosphorylation and then inhibiting NF-κB signaling pathway. |
| CFN98538 | Isocolumbin Isocolumbin has anti-inflammatory, and antimicrobial activities. |
| CFN98540 | Oroxylin A Oroxylin A has anticancer,.anti-inflammation, antithrombotic,antibacterial, anti-pruritic effects, it can inhibit LPS-induced iNOS and COX-2 gene expression by blocking NF-κB activation. Oroxylin A reverses MDR by G2/M arrest and the underlying mechanism attributed to the suppression of P-gp expression via Chk2/P53/NF-κB signaling pathway. Oroxylin A facilitates memory consolidation through brain-derived neurotrophic factor (BDNF)-TrkB signaling. |
| CFN98493 | Jatrorrhizine Jatrorrhizine has neuroprotective, antioxidative, anti-inflammatory, antihypercholesterolemic, and anti-hyperglycemia effects.Jatrorrhizine is expected to be developed as a new gastric prokinetic drug, it is metabolized by human CYP1A2 and multiple UGT1A isoforms. It has inhibitory activities against the expression of inducible NO syntase (iNOS) and cyclooxygenase-2 (COX-2), and can improve the utilization and excretion of cholesterol by up-regulating the mRNA and protein expression of LDLR and CYP7A1. |
